THE EFFECTIVENESS OF ULINASTATIN IN PATIENTS WITH CHRONIC PANCREATITIS
Authors/Creators
- 1. Doctor of Medical Sciences, Professor. Head of the Department of Gastroenterology of the Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation, Tashkent, Uzbekistan
- 2. Doctor of Medical Sciences, Senior researcher. Professor of Rehabilitation, Folk Medicine and Physical Education Department of the Tashkent Medical Academy, Tashkent, Uzbekistan
- 3. Doctor of Medical Sciences, Gastroenterologist of Department of Gastroenterology of the Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation, Tashkent, Uzbekistan
Description
Abstract
The article presents the results of the anti-inflammatory efficacy of the new generation protease inhibitor ulinastatin in the treatment of exacerbation of chronic pancreatitis of moderate severity. It is shown that exacerbation of chronic pancreatitis of alimentary, alcoholic and biliary etiology was expressed by abdominal pain and dyspeptic symptoms. An increase in the level of serum aminotransferases, bilirubin and alpha amylase was noted, which was accompanied by a significant increase in the activity of pro-inflammatory cytokines. The use of ulinastatin in the complex of pharmacotherapy of chronic pancreatitis contributed to the effective relief of exacerbation of pancreatitis, which was due to the anticytokine effect of the drug.
Files
NJD_95-50-53.pdf
Additional details
References
- 1. Белякова С.В. Социально-демографическая и клиническая характеристика больных хроническим панкреатитом в Московской области. Дис. Канд. Наук., Москва. 2019. С.1-149.
- 2. Singh VK, Yadav D, Garg PK. Diagnosis and Management of Chronic Pancreatitis: A Review. JAMA. 2019 Dec 24;322(24):2422-2434. doi: 10.1001/jama.2019.19411. PMID: 31860051.
- 3. Karimov M.M., Zufarov P.S., Sobirova G.N., Pulatova N.I., Aripdjanova Sh.S. // Ulinastatin in the conservative therapy of chronic pancreatitis/ Central Asian Journal of Medicine 2, 2022 P. 54-61 .
- 4. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies / Xiao AY, Tan ML, Wu LM [et al.] // Lancet Gastroenterol Hepatol . –2016. - Vol. 1(1). – P. 45-55.
- 5. The incidence and aetiology of acute pancreatitis across Europe / S E Roberts, S. Morrison-Rees, A. John [et al.]// Pancreatology. –2017. - Vol. 17, No. 2. – P. 155-165.
- 6. Update on pathogenesis and clinical management of acute pancreatitis / DM Cruz- Santamaría, C. Taxonera, M. Giner // World J Gastrointest Pathophysiol. - 2012. - Vol . 3(3). – P. 60-70.
- 7. Role of Ulinastatin, a trypsin inhibitor, in severe acute pancreatitis in critical care setting: A ¬¬retrospective analysis. / Lagoo JY, D'Souza MC, Kartha A., Kutappa AM // J Crit Care. - 2018. - No. 45. - P. 27-32.
- 8. Ulinastatin ameliorates tissue damage of severe acute pancreatitis through modulating regulatory T cells / Pan Y., Fang H., Lu F. [et al.] // J Inflamm (Lond). - 2017. -Vol.14.–P.7. doi: 10.1186/s12950-017-0154-7.
- 9. Effect of ulinastatin on serum levels of tumor necrosis factor-α, P-selectin, and thrombin-antithrombin complex in young rats with sepsis / Liu Y., Wu XH // Zhongguo Dang Dai ErKe Za Zhi. - 2017. - Vol. 19(2). – P. 237-241.